| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 67, 1060-1063, Copyright © 1988 by Endocrine Society
ARTICLES |
M Kusunoki, T Yamamura, S Ichii, S Fujita, T Nakai and J Utsunomiya
Second Department of Surgery, Hyogo College of Medicine, Japan.
To determine the role of gamma-aminobutyric acid (GABA) in islet tissue, sodium valproate (1600 mg/day) was administered for 6 days to 10 normal subjects and 1 patient with a somatostatinoma. Plasma valproate concentrations reached a steady state by the third day accompanied by elevation of plasma GABA concentrations. Sodium valproate administration resulted in a 40% decrease in plasma somatostatin concentrations in the normal subjects and a 63% decrease in the somatostatinoma patient, respectively, compared to the response to placebo. Plasma C-peptide concentrations did not change in any subject. Fasting blood glucose levels decreased in the somatostatinoma patient during sodium valproate administration. These results suggest that endogenous GABA may play some role in the release of somatostatin, but not in the release of insulin.
This article has been cited by other articles:
![]() |
A. Verrotti, F. Basciani, M. De Simone, D. Trotta, G. Morgese, and F. Chiarelli Insulin Resistance in Epileptic Girls Who Gain Weight After Therapy With Valproic Acid J Child Neurol, April 1, 2002; 17(4): 265 - 268. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |